A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).

Authors

null

Jacek K. Pinski

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Jacek K. Pinski , Andrew V. Schally , Denice D Tsao-Wei , Tanya B. Dorff , Susan G. Groshen , Shigang Xiong , David I. Quinn , Yu-Chong Tai , Juergen Engel , Stephen V. Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01240629

Citation

J Clin Oncol 31, 2013 (suppl; abstr 5062)

DOI

10.1200/jco.2013.31.15_suppl.5062

Abstract #

5062

Poster Bd #

38E

Abstract Disclosures

Similar Posters

First Author: Mamta Parikh

Poster

2012 Genitourinary Cancers Symposium

A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.

A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.

First Author: Stephen V. Liu